Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helkort
- Development stage
- Unknown
- Lead developer
- Apeks Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Helkort is a topical antibiotic cream containing 2% fusidic acid, marketed by the Turkish company **Apeks Pharma** and manufactured by **İlko İlaç**. It is indicated for the treatment of various bacterial skin infections, such as impetigo, folliculitis, and infected dermatitis, particularly those caused by *Staphylococcus aureus*. The active ingredient, fusidic acid, works by inhibiting bacterial protein synthesis. It specifically binds to **elongation factor G (EF-G)** on the ribosome, preventing the translocation of the ribosome along the mRNA and the subsequent release of the EF-G-GDP complex, which effectively halts the elongation of the polypeptide chain. Helkort is typically supplied in 20-gram tubes for dermatological use.
- Brand names
- Helkort
Beyond the preview
Go deeper on Helkort.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helkort.